Original Article
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
N Engl J Med 2006; 354:251-260January 19, 2006
- Abstract
Background
Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere.
Methods
We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir–emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine–lamivudine group). The primary end point was the proportion of patients without baseline resistance to efavirenz in whom the HIV RNA level was less than 400 copies per milliliter at week 48 of the study.
Results
Through week 48, significantly more patients in the tenofovir–emtricitabine group reached and maintained the primary end point of less than 400 copies of HIV RNA per milliliter than did those in the zidovudine–lamivudine group (84 percent vs. 73 percent, respectively; 95 percent confidence interval for the difference, 4 to 19 percent; P=0.002). This difference excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen, indicating a significantly greater response with this regimen. Significant differences were also seen in the proportion of patients with HIV RNA levels of less than 50 copies per milliliter (80 percent in the tenofovir–emtricitabine group vs. 70 percent in the zidovudine–lamivudine group; 95 percent confidence interval for the difference, 2 to 17 percent; P=0.02) and in increases in CD4 cell counts (190 vs. 158 cells per cubic millimeter, respectively; 95 percent confidence interval for the difference, 9 to 55; P=0.002). More patients in the zidovudine–lamivudine group than in the tenofovir–emtricitabine group had adverse events resulting in discontinuation of the study drugs (9 percent vs. 4 percent, respectively; P=0.02). In none of the patients did the K65R mutation develop.
Conclusions
Through week 48, the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs. (ClinicalTrials.gov number, NCT00112047.)
Media in This Article
Figure 1
Characteristics of Patients at Baseline and at Week 48.Figure 2
Proportion of Patients with HIV RNA Levels below 400 Copies per Milliliter.Article Activity
- Article
Highly active antiretroviral therapy has fundamentally altered the course of human immunodeficiency virus (HIV) infection by making it possible to suppress the plasma viral load below the limit of detection and to increase the number of CD4 cells.1 The cornerstone of durable suppression of HIV replication is maintenance of a potent and tolerable regimen to which the patient can adhere. Adherence is necessary to prevent the emergence and replication of drug-resistant strains of the virus.2
Current guidelines for the management of HIV infection recommend the use of zidovudine or tenofovir disoproxil fumarate (DF) with lamivudine or emtricitabine as preferred nucleoside reverse-transcriptase inhibitors (NRTIs) along with the nonnucleoside reverse-transcriptase inhibitor (NNRTI) efavirenz.3 Our study compared the efficacy and tolerability of two regimens, efavirenz plus a fixed dose of zidovudine and lamivudine or efavirenz plus tenofovir DF and emtricitabine.
Methods
Study Design
We conducted a prospective, randomized, multicenter noninferiority study comparing the regimens of tenofovir DF, emtricitabine, and efavirenz and a fixed dose of zidovudine and lamivudine plus efavirenz at sites in France, Germany, Italy, Spain, the United Kingdom, and the United States. An institutional review board or an ethics committee at each site approved the study protocol and the informed-consent form. Each participant gave written informed consent.
Adult patients (defined as persons 18 years of age or older) were considered for inclusion in this open-label study if they had never received antiretroviral treatment and had plasma HIV RNA levels greater than 10,000 copies per milliliter. Patients had to meet the following criteria: estimated glomerular filtration rate (GFR) (measured according to the Cockcroft–Gault method4) no lower than 50 milliliters per minute (0.84 milliliter per second); aminotransferase levels, no more than three times the upper limit of the normal range (alanine aminotransferase: 6 to 43 U per liter in men; 6 to 34 U per liter in women; aspartate aminotransferase: 11 to 36 U per liter in men; 9 to 34 U per liter in women); total bilirubin level, no more than 1.5 mg per deciliter (25.65 μmol per liter); absolute neutrophil count, no lower than 1000 per cubic millimeter; hemoglobin, no lower than 8.0 g per deciliter; platelet count, no lower than 50,000 per cubic millimeter; serum amylase level, no more than 1.5 times the upper limit of the normal range (28 to 100 U per liter for patients 18 to 50 years of age; 28 to 120 U per liter for patients 50 to 60 years of age; 28 to 150 U per liter for patients 60 to 70 years of age); and serum phosphorus level, no lower than 2.2 mg per deciliter (0.71 mmol per liter). No minimum CD4 cell count was required.
Patients were excluded if a new condition defining the acquired immunodeficiency syndrome had been diagnosed within 30 days before entry into the study (except on the basis of CD4 criteria), if they were receiving ongoing therapy with nephrotoxic drugs (e.g., aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, and intravenous pentamidine) or agents that interact with efavirenz (e.g., astemizole, terfenadine, dihydroergotamine, ergotamine, midazolam, triazolam, cisapride, rifampin, ergonovine, and methylergonovine), if they were pregnant or lactating, if they had a history of clinically significant renal or bone disease or malignant disease other than Kaposi's sarcoma or basal-cell carcinoma, or if they had a life expectancy of less than one year. All patients were required to use an effective method of contraception while receiving the study treatment and for 30 days after completion of the study regimen. The trial was extended from 48 to 144 weeks.
Patients were stratified according to baseline CD4 cell count (<200 vs. ≥200 cells per cubic millimeter) but not according to site or country, and patients were randomly assigned centrally by an interactive voice-response system in a one-to-one ratio to receive either a once-daily regimen of efavirenz (600 mg; Sustiva, Bristol-Myers Squibb) plus tenofovir DF (300 mg; Viread, Gilead Sciences) and emtricitabine (200 mg; Emtriva, Gilead Sciences) as separate components (to be taken without regard to meals and preferably at bedtime) or to a regimen of efavirenz (600 mg) once daily and a fixed dose of zidovudine (300 mg) and lamivudine (150 mg; Combivir, GlaxoSmithKline) twice daily, in an open-label manner. Nevirapine (200 mg; Viramune, Boehringer Ingelheim) twice daily could be substituted for efavirenz in the presence of intolerable central nervous system side effects.
Clinical examinations and laboratory analyses were conducted at the screening visit, before the baseline visit, at the baseline visit (when administration of the study drugs was initiated), at weeks 2, 4, and 8, and then every 8 weeks through the 48 weeks of the study or, for patients who discontinued participation in the study early, at 30 days after discontinuation. Adherence was assessed on the basis of pill counts at each visit by study coordinators or nurses at each site. A physical examination (including evaluation for hyperpigmentation) was performed at each visit. Other assessments included CD4 cell counts, measurement of plasma HIV RNA levels (Amplicor HIV-1 Monitor Test, version 1.5, Roche Diagnostics), hematology and plasma chemistry profiles, urinalysis, and a fasting lipid panel. The protocol was amended before week 48, at which point lipodystrophy assessments by whole-body dual-energy x-ray absorptiometry were performed in a subgroup of 100 patients. These scans were read centrally by radiologists who were unaware of the treatment assignments.
The clinical data were gathered by Charles River Laboratories. The study was designed by and the data were analyzed at Gilead Sciences. All authors had full access to the data and vouch for the accuracy and completeness of the data and the analyses. The manuscript was written by all the authors, each of whom contributed to the drafts and revisions and all of whom approved the final manuscript.
Efficacy Analysis
The primary objective was to assess the noninferiority of the regimen of tenofovir DF, emtricitabine, and efavirenz to the regimen of zidovudine, lamivudine, and efavirenz as measured by HIV RNA levels of less than 400 copies per milliliter through week 48, defined according to the algorithm of the Food and Drug Administration (FDA) for the time to loss of virologic response, which requires confirmation (two consecutive values) of response or of no response (missing data or early termination of participation in the study was considered to be failure).5 The 487 eligible patients without baseline resistance to efavirenz who underwent randomization and received treatment were the predefined population for the primary end-point analysis. The secondary objective was to assess the noninferiority of tenofovir DF, emtricitabine, and efavirenz to zidovudine, lamivudine, and efavirenz as assessed by HIV RNA levels of less than 50 copies per milliliter and changes in the CD4 cell count.
Safety Analysis
All patients who received at least one dose of the study medications were included in the primary safety analysis, which evaluated events that occurred from the initiation of the assigned study regimen to 30 days after discontinuation of the regimen. The severity of adverse events and laboratory abnormalities was graded according to a modified Common Toxicity Criteria of the National Institutes of Allergy and Infectious Diseases.6
Resistance Analysis
HIV type 1 genotyping was performed on blood samples obtained at baseline in batches for all patients. Genotypic and phenotypic resistance analyses were also performed for patients who met the following criteria: they continued to receive the assigned study drugs and had no less than 400 copies per milliliter of HIV RNA as measured on at least two consecutive visits after achieving levels no more than 400 copies per milliliter on at least one occasion (viral rebound); they continued the assigned study drugs and had HIV RNA levels no lower than 400 copies per milliliter at week 48; or they discontinued the assigned study drugs before week 48 and had HIV RNA levels no lower than 400 copies per milliliter on their last visit (before discontinuing the study drugs).
Statistical Analysis
The regimen of tenofovir DF, emtricitabine, and efavirenz was to be considered not inferior to the regimen of zidovudine, lamivudine, and efavirenz if the lower bound of the 95 percent confidence interval for the difference between the two groups, those receiving tenofovir DF, emtricitabine, and efavirenz (the tenofovir–emtricitabine group) minus those receiving zidovudine, lamivudine, and efavirenz (the zidovudine–lamivudine group) for the primary end point (in the proportion of patients with an HIV RNA level of less than 400 copies per milliliter) was no lower than −13 percent. Assuming a response rate of 70 percent at week 48 for the zidovudine, lamivudine, and efavirenz regimen and a one-sided type I error of 2.5 percent, the planned sample size of 500 patients provided the study with 85 percent power to demonstrate the noninferiority of the tenofovir DF, emtricitabine, and efavirenz regimen. Substitution of nevirapine for efavirenz was not classified as treatment failure. The two treatment groups were compared with use of the Cochran–Mantel–Haenszel test for categorical data and by the Wilcoxon rank-sum test for continuous data. Analyses of CD4 data and safety laboratory data included patients who received the assigned regimens. All statistical analyses were performed with the use of SAS software, version 8.2 (SAS Institute), at Gilead Sciences. Two interim analyses (submitted to health regulatory authorities) at weeks 16 and 24 were performed by Gilead Sciences. There were no stopping rules. All reported P values are two-sided and were not adjusted for multiple testing.
Results
During the recruitment period from July 2003 to January 2004, 517 patients at 67 sites were randomly assigned to receive efavirenz and either tenofovir DF and emtricitabine or a fixed dose of zidovudine and lamivudine. All visits for the 48-week study were completed by December 2004. The disposition and baseline characteristics of the two treatment groups are shown in Figure 1Figure 1
Characteristics of Patients at Baseline and at Week 48.. Eight patients were excluded from the intention-to-treat population, two because they had previously received antiretroviral treatment and six because they never received the assigned study medication. The median number of patients per site was 12 (range, 1 to 38). In 19 patients (10 assigned to the tenofovir–emtricitabine group and 9 assigned to the zidovudine–lamivudine group), nevirapine was substituted for efavirenz because of treatment-related side effects of efavirenz.During the trial, 22 patients (11 in each of the two groups) were found to have HIV mutations associated with resistance to efavirenz (K103N in 17 patients) at entry into the study. For this reason, data on two populations of eligible, treated patients randomly assigned to treatment were analyzed statistically — 509 patients with or without baseline NNRTI resistance and 487 patients without baseline NNRTI resistance.
Response to Treatment
At week 48, 206 of the 244 patients (84 percent) in the tenofovir–emtricitabine group and 177 of the 243 patients in the zidovudine–lamivudine group (73 percent) reached and maintained HIV RNA levels of less than 400 copies per milliliter, which was the primary end point (Figure 2Figure 2
Proportion of Patients with HIV RNA Levels below 400 Copies per Milliliter.). The 95 percent confidence interval for the difference between the two groups was 4 to 19 percent (P=0.002), which excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen. The confidence interval for the difference also excludes zero, indicating a significantly greater response with the tenofovir DF, emtricitabine, and efavirenz regimen. At week 48, 194 of 244 patients (80 percent) in the tenofovir–emtricitabine group and 171 of 243 patients in the zidovudine–lamivudine group (70 percent) reached and maintained HIV RNA levels of less than 50 copies per milliliter. The 95 percent confidence interval for the difference between the two groups was 2 to 17 percent (P=0.02), which excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen and indicates a significantly greater response with this regimen. Similar statistically significant differences were observed in the intention-to-treat population (509 patients) on the basis of HIV RNA levels of less than 400 copies per milliliter (81 percent in the tenofovir–emtricitabine group vs. 70 percent in the zidovudine–lamivudine group; 95 percent confidence interval for the difference, 3 to 18 percent; P=0.005) or HIV RNA levels of less than 50 copies per milliliter (77 percent vs. 68 percent, respectively; 95 percent confidence interval for the difference, 1 to 16 percent; P=0.03).At week 48, the patients treated with the tenofovir DF, emtricitabine, and efavirenz regimen had significantly greater increases from baseline in absolute CD4 cell counts (mean increase, 190 vs. 158 cells per cubic millimeter; 95 percent confidence interval for the difference, 9 to 55; P=0.002) and in median percentages of CD4 lymphocytes (CD4 percentage) (11 percent in the tenofovir–emtricitabine group vs. 10 percent in the zidovudine–lamivudine group, P=0.02). On the basis of pill counts, the mean adherence to treatment was greater among patients receiving the tenofovir DF, emtricitabine, and efavirenz regimen (90 percent) than among those receiving the zidovudine, lamivudine, and efavirenz regimen (87 percent, P=0.04).
Genotypic Analysis
Genotypic data were collected on 35 patients who met the criteria for resistance analyses. Overall, there were no significant differences between the two groups (Table 1Table 1
Genotypic Analysis through 48 Weeks of Treatment.). Of mutations resulting from exposure to reverse-transcriptase inhibitors, M184V/I, which can be selected by either lamivudine or emtricitabine, was detected in two patients in the tenofovir–emtricitabine group, as compared with seven patients in the zidovudine–lamivudine group. K65R, which can be selected by tenofovir DF, was not detected in the 34 patients for whom genotypic data were available (12 patients in the tenofovir–emtricitabine group and 22 patients in the zidovudine–lamivudine group).There were no significant differences in the frequency of viral rebound (confirmed by HIV RNA levels of >400 copies per milliliter) between the two groups (3 percent [7 of 244 patients] in the zidovudine–lamivudine group and 1 percent [2 of 243 patients] in the tenofovir–emtricitabine group, P=0.11). In eight of the nine patients who had viral rebound, resistance mutations developed (two patients in the tenofovir–emtricitabine group [one with a wild-type mutation, the other with an efavirenz-resistance mutation] and seven patients in the zidovudine–lamivudine group [all seven had an efavirenz-resistance mutation, five had M184V/I, and one had a thymidine analogue mutation]).
Safety and Tolerability
The safety analysis is based on 511 patients who received any study medications (Figure 1). Adverse events (severity grades 2 through 4 according to the modified Common Toxicity Criteria) occurred in 163 of 257 patients (63 percent) in the tenofovir–emtricitabine group and in 161 of 254 patients (63 percent) in the zidovudine–lamivudine group (Table 2Table 2
Adverse Events (Grades 2 through 4) and Laboratory Abnormalities (Grades 2 through 4) through 48 Weeks.). Laboratory abnormalities (grades 2 through 4) arose in 142 of 254 patients (56 percent) in the tenofovir–emtricitabine group and 142 of 251 patients (57 percent) in the zidovudine–lamivudine group (Table 2).Significantly more patients in the zidovudine–lamivudine group had adverse events that resulted in discontinuation of study medications (P=0.02) (Figure 1 and Table 3Table 3
Adverse Events Resulting in Discontinuation in the Safety Population through 48 Weeks.). The most common cause of discontinuation of the zidovudine, lamivudine, and efavirenz regimen was marked anemia (14 patients vs. 0 in the tenofovir–emtricitabine group; P<0.001). Among these 14 patients, the median hemoglobin level at baseline was 13.8 g per deciliter (range, 10.8 to 16.0), which dropped to a nadir of 6.9 g per deciliter (range, 3.7 to 9.3) before discontinuation of the zidovudine, lamivudine, and efavirenz regimen. Seven patients received erythropoietin before discontinuation and seven patients received transfusions. Of these 14 patients, 1 was black and 13 were male; the mean CD4 count at baseline was 95 cells per cubic millimeter (range, 4 to 294). There were no obvious coexisting medical conditions or non-antiretroviral medications that might have contributed to their anemia.We closely followed markers of renal function. Renal safety was similar in the two groups over the 48 weeks of the study, and no patient discontinued study drugs because of renal events. There were changes in the two groups in the median GFR, as measured by the Cockcroft–Gault method4 or the modification of diet in renal disease7 equations, from baseline to week 48 (Cockcroft–Gault method: change in GFR in the tenofovir–emtricitabine group, −1 ml per minute [−0.02 ml per second]; and in the zidovudine–lamivudine group, +6 ml per minute [0.1 ml per second]; modification of diet in renal disease equations: change in the two groups, less than −1 ml per minute per 1.73 m2). There were no confirmed abnormalities graded for severity in serum levels of creatinine or phosphorus in the tenofovir–emtricitabine group, but toxic levels were found in three patients (1 percent) in the zidovudine–lamivudine group. There were no cases of Fanconi's syndrome.
Hyperpigmentation was confirmed or could not be ruled out in seven patients in the tenofovir–emtricitabine group and four in the zidovudine–lamivudine group (P=0.54). All cases were mild except that in one patient in the zidovudine–lamivudine group. No patient discontinued the study drugs because of hyperpigmentation.
Patients in the tenofovir–emtricitabine group had a lower mean increase from baseline in fasting total cholesterol levels (21 mg per deciliter [0.54 mmol per liter]) than did those in the zidovudine–lamivudine group (35 mg per deciliter [0.91 mmol per liter]; P<0.001) and fasting low-density lipoprotein cholesterol levels (13 mg per deciliter [0.34 mmol per liter] vs. 20 mg per deciliter [0.52 mmol per liter]; P=0.01). The increase from baseline in fasting high-density lipoprotein levels was significantly higher in the zidovudine–lamivudine group (9 mg per deciliter [0.23 mmol per liter]) than in the tenofovir–emtricitabine group (6 mg per deciliter [0.16 mmol per liter], P=0.004). The increase from baseline in mean fasting triglyceride levels was not significantly different in the two groups (3 mg per deciliter [0.03 mmol per liter] in the tenofovir–emtricitabine group vs. 31 mg per deciliter [0.35 mmol per liter] in the zidovudine–lamivudine group, P=0.38).
Patients in the two groups entered the trial with the same mean weight (76 kg [168 lb]). Through week 48, patients in the tenofovir–emtricitabine group had an increase from baseline in mean weight of 2.1 kg (4.6 lb), as compared with 1.1 kg (2.4 lb) among those in the zidovudine–lamivudine group (P=0.14). At week 48, as measured by dual-energy x-ray absorptiometry, total limb fat was significantly less in a subgroup of 49 patients in the zidovudine–lamivudine group who underwent scanning than in a subgroup of 51 patients in the tenofovir–emtricitabine group (mean, 6.9 kg [15.2 lb] vs. 8.9 kg [19.6 lb]; P=0.03).
Discussion
In this large, randomized trial, the tenofovir DF, emtricitabine, and efavirenz regimen fulfilled the criteria for noninferiority to the zidovudine, lamivudine, and efavirenz regimen. The results also indicate significantly greater responses to the tenofovir DF, emtricitabine, and efavirenz regimen (as defined by the FDA's algorithm for the time to loss of viral response) as compared with the well-established regimen of zidovudine, lamivudine, and efavirenz.8,9 The regimens also differed in their effect on immune reconstitution: in the tenofovir–emtricitabine group, there was a significantly greater increase in the total CD4 cell counts and the CD4 percentages.
The data collected over the 48 weeks of the study indicate greater tolerability of the tenofovir DF and emtricitabine backbone and the potential for clinically significant anemia associated with zidovudine. These results are not surprising, because the efficacy, tolerability, and toxicity profiles of these drugs are consistent with profiles observed in other studies.8-11 Renal adverse events have been reported with antiretroviral regimens containing tenofovir DF.12-16 However, the overall renal safety profile in the group receiving tenofovir DF in our study was favorable, as has been reported in other long-term studies of this agent.10,17
In a subgroup of patients who underwent dual-energy x-ray absorptiometry, those in the tenofovir–emtricitabine group had significantly more limb fat at week 48 than those in zidovudine–lamivudine group. Declines in limb fat have not been seen in patients receiving initial long-term antiretroviral therapy with a tenofovir DF, lamivudine, and efavirenz regimen.10,17 Fat loss in patients receiving a regimen containing zidovudine has been previously reported.18,19 Lipoatrophy has also been associated in multiple studies with the use of stavudine, another thymidine analogue.20-22 Although some studies have reported improvement in lipoatrophy with the substitution of other NRTIs for thymidine analogues, the increase in limb fat was <1 kg (2.2 lb) after 48 weeks.23-25 Thus, avoiding therapy with antiretroviral agents that are associated with lipoatrophy may be preferable to changing therapy in response to lipoatrophy. We do not yet know whether data from this study at 96 and 144 weeks will show significant differences in long-term toxic effects, specifically lipoatrophy and hyperlipidemia, as was seen in Study 903 (a three-year, double-blind comparison between an antiretroviral regimen consisting of stavudine, lamivudine, and efavirenz with a tenofovir DF, lamivudine, and efavirenz regimen).10 A preliminary analysis of a subgroup of 255 patients in our study population who have completed 96 weeks of therapy suggests that the differences in limb fat seen at 48 weeks persist, with further loss of limb fat as measured by dual-energy x-ray absorptiometry in the zidovudine–lamivudine group.
The results with regard to resistance were unexpected. The lack of emergence of the K65R mutation in the tenofovir–emtricitabine group is in contrast to the results of Study 903, in which 7 of 299 patients had K65R mutations at 48 weeks.10,26 In addition, the M184V mutation occurred in only two patients in the tenofovir–emtricitabine group, as compared with seven in the zidovudine–lamivudine group. Whether these differences can be explained by the greater potency or the longer half-life of emtricitabine, as compared with lamivudine, is unclear. Approximately 5 percent of the patients in our international, multicenter study who had not previously received antiretroviral therapy had NNRTI resistance at baseline. Consistent with published international guidelines, these data provide support for baseline resistance testing before the initiation of antiretroviral therapy.27
Tenofovir DF and emtricitabine were administered once daily as separate agents in this trial, but a fixed-dose combination of emtricitabine and tenofovir DF that may further improve adherence is now available.
This study, involving HIV-infected patients who had not previously received antiretroviral therapy, directly compared the efficacy and safety at 48 weeks of two antiretroviral regimens that are now classified as “preferred” in the treatment guidelines of the Department of Health and Human Services.3 The superior outcome in the tenofovir–emtricitabine group in the study provides further support for the use of this regimen in patients who have not previously received antiretroviral therapy. These findings have important implications for the choice of an initial nucleoside-analogue backbone in the treatment of such patients.
Dr. Gallant reports having received consulting fees and lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline and grant support from Boehringer Ingelheim, Bristol-Myers Squibb, and Gilead Sciences; Drs. DeJesus and Gazzard, consulting fees and lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline; Drs. Arribas and Pozniak, consulting fees and lecture fees from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline; and Dr. Campo, consulting fees from Gilead Sciences and grant support from Gilead Sciences and Bristol-Myers Squibb. Drs. Lu, McColl, Chuck, Enejosa, Toole, and Cheng are employees of and hold stock in Gilead Sciences. No other potential conflict of interest relevant to this article was reported.
We are indebted to the patients who participated in the study.
Source Information
From the Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore (J.E.G.); the Orlando Immunology Center, Orlando, Fla. (E.D.); Hospital de La Paz, Madrid (J.R.A.); Chelsea and Westminster Hospital, London (A.L.P., B.G.); the University of Miami, Miami (R.E.C.); and Gilead Sciences, Foster City, Calif. (B.L., D.M., S.C., J.E., J.J.T., A.K.C.).
Address reprint requests to Dr. Gallant at the Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E. Monument St., Rm. 443, Baltimore, MD 21287, or at jgallant@jhmi.edu.
Other members of the Study 934 Group are listed in the Appendix.
Appendix
In addition to the authors, other participants in the Study 934 Group were the following: A. Diamond AIDS Research Center, New York City — M. Markowitz; AIDS Healthcare Foundation, Los Angeles — H. Khanlou; Albany Medical College, Albany, N.Y. — G. Drusano, R. Liporace; Beth Israel Deaconess Medical Center, Boston — M. Albrecht; Boston University Medical Center, Boston — P. Skolnik; Brighton and Sussex University Hospitals, Brighton, United Kingdom — M. Fisher; Capital Medical Associates, Washington, D.C. — B. Rashbaum; Centre Hospitalier Universitaire de Nice-L'Archet, Nice, France — P. Dellamonica; Community Research Initiative of New England, Springfield, Mass. — A.B. Morris; CORE Center, Chicago — D.E. Barker; Drexel University College of Medicine, Philadelphia — D.F. Alvarez; Dupont Circle Physicians Group, Washington, D.C. — D. Ward; Emory University and Grady Infectious Disease Program, Atlanta — J.L. Lennox; Ft. Lauderdale, Fla. — G. Richmond; Hampton Roads Medical Specialists, Hampton, Va. — S.L. Green; Henry Ford Hospital, Detroit — I. Brar; Hôpital Gui-de-Chauliac, Montpellier, France — J. Reynes; Hôpital Purpan, Toulouse, France — P. Massip; Hôpital Tenon, Paris — W. Rozenbaum; Hospital de la Santa Creu i Sant Pau, Barcelona — P. Domingo; Hospital St. Raffaele University, Milan — A. Lazzarin; Hospital Vall d'Hebron, Barcelona — E. Ribera; Infectious Disease of Indiana, Indianapolis — J. Fraiz; Infectious Disease Research Institute, Tampa, Fla. — B.G. Yangco; Infectious Disease Specialists of Atlanta, Decatur, Ga. — R.H. Dretler; Infectious Diseases Associates of Houston, Houston — T.C. Samo; Infectious Diseases Associates, Sarasota, Fla. — V. Vega; IPM Study Center, Hamburg, Germany — L. Weitner; Jemsek Clinic, Huntersville, N.C. — J.G. Jemsek; Johann Wolfang Goethe-Universität, Frankfurt, Germany — S. Staszewski; Kaiser Permanente Medical Group, Sacramento, Calif. — J. Flamm; Kaiser Permanente Medical Group, San Francisco — S. Follansbee; Living Hope Clinical Foundation, Long Beach, Calif. — S. Schneider; Louisiana State University Health Sciences Center HIV Outpatient Clinic Clinical Research, New Orleans — R. Clark; Massachusetts General Hospital, Boston — K. Zachary; Montrose Clinic, Houston — S. Schrader; N.C. Bellos, Dallas; North Broward Hospital District, Ft. Lauderdale, Fla. — M. Sension; North Texas Center for AIDS and Clinical Research, Dallas — J.D. Brand; NorthStar Medical Center, Chicago — D.S. Berger; Ohio State University, Columbus — M.F. Para; Ospedale Amedo di Savoia, Torino, Italy — G. Di Perri; Pacific Horizon Medical Group, San Francisco — L. Thornton; Pacific Oaks Medical Group, Beverly Hills, Calif. — P.R. Wolfe; Phoenix Body Positive, Phoenix, Ariz. — R.A. Myers; Puerto Rico Network in Clinical Research on AIDS, San Juan — L. Santiago; Rose Medical Center, Denver — B. Young; Royal Free Hospital, London — M.A. Johnson; San Juan Veterans Affairs Hospital, San Juan, Puerto Rico — C.R. Rivera-Vázquez, S. Saavedra; South Florida Clinical Research, Atlantis, Fla. — L.M. Bush; St. Joseph's Comprehensive Research Institute, Tampa, Fla. — D. Norris; St. Thomas' Hospital, London — A. de Ruiter; Steinhart Medical Associates and Mercy Hospital, Miami — C. Steinhart; Therapeutic Concepts, Houston — J.C. Gathe; Tower ID [Infectious Disease] Medical Associates, Los Angeles — R. Stryker; Treasure Coast Infectious Disease Consultants, Vero Beach, Fla. — G. Pierone; University of California, San Diego — S. Letendre; University of North Carolina at Chapel Hill, Chapel Hill — D.A. Wohl; University of Southern California Keck School of Medicine, Los Angeles — K.E. Squires, R. Larsen; University of Texas Health Science Center at Houston, Houston — B.J. Barnett; Veterans Affairs Medical Center Washington, D.C. — A.M. Labriola; Wake Forest University School of Medicine, Winston-Salem, N.C. — S. Pegram; Gilead Sciences, Foster City, Calif. — S.-S. Chen, S.-M. Chuang, B. Doherty, V. Ho, H.S. Jaffe, S. Liaw, V. Marchesin, N.A. Margot, G. Mattiuzzo, M.D. Miller, J.F. Rooney, J. Sayre, S. Wong, M. Wulfsohn.
- References
References
1
Palella FJ Jr ,Delaney KM ,Moorman AC , et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860
Full Text | Web of Science | Medline2
Sethi AK ,Celentano DD ,Gange SJ ,Moore RD ,Gallant JE . Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-1118
CrossRef | Web of Science | Medline3
Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, D.C.: Department of Health and Human Services, December 23, 2005. (Accessed December 23, 2005, at http://AIDSinfo.nih.gov.)
4
Cockcroft DW ,Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
CrossRef | Medline5
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements — clinical considerations for accelerated and traditional approval. Washington, D.C.: Department of Health and Human Services, October 2002. (Accessed December 23, 2005, at http://www.fda.gov/cder/guidance.)
6
Regulatory Compliance Center. Division of AIDS (DAIDS) table of grading severity of adult adverse experiences. Bethesda, Md.: National Institute of Allergy and Infectious Diseases, August 1992. (Accessed December 23, 2005, at http://rcc.tech-res-intl.com/tox_tables.htm.)
7
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
Web of Science | Medline8
Staszewski S ,Morales-Ramirez J ,Tashima KT , et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873
Full Text | Web of Science | Medline9
Robbins GK ,De Gruttola V ,Shafer RW , et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-2303
Full Text | Web of Science | Medline10
Gallant JE ,Staszewski S ,Pozniak AL , et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201
CrossRef | Web of Science | Medline11
DeJesus E ,Herrera G ,Teofilo E , et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV infected adults. Clin Infect Dis 2004;39:1038-1046
CrossRef | Web of Science | Medline12
Verhelst D ,Monge M ,Meynard JL , et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-1333
CrossRef | Web of Science | Medline13
Karras A ,Lafaurie M ,Furco A , et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073
CrossRef | Web of Science | Medline14
Creput C ,Gonzalez-Canali G ,Hill G ,Piketty C ,Kazatchkine M ,Nochy D . Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-937
CrossRef | Web of Science | Medline15
Rollot F ,Nazal EM ,Chauvelot-Moachon L , et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-e176
CrossRef | Web of Science | Medline16
Gallant JE ,Parish MA ,Keruly JC ,Moore RD . Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198
CrossRef | Web of Science | Medline17
Cassetti I, Madruga JVR, Suleiman JMAH, Zhong L, Enejosa J, Cheng AK. Tenofovir DF in combination with lamivudine and efavirenz in antiretroviral naive patients: a 4 year follow-up. In: Program and abstracts of the 3rd IAS [International AIDS Society] Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24–27, 2005.
18
Mallal SA ,John M ,Moore CB ,James IR ,McKinnon EJ . Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316
CrossRef | Web of Science | Medline19
Bogner JR ,Vielhauer V ,Beckman RA , et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27:237-244
CrossRef | Web of Science | Medline20
Dube MP ,Parker RA ,Tebas P , et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-1818
CrossRef | Web of Science | Medline21
Saint-Marc T ,Partisani M ,Poizot-Martin I , et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49
CrossRef | Web of Science | Medline22
Heath KV ,Hogg RS ,Singer J ,Chan KJ ,O'Shaughnessy MV ,Montaner JS . Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002;30:440-447
CrossRef | Web of Science | Medline23
McComsey GA ,Ward DJ ,Hessenthaler SM , et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-270
CrossRef | Web of Science | Medline24
Martin A ,Smith DE ,Carr A , et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-1036
CrossRef | Web of Science | Medline25
Moyle G, Sabin C, Cartledge J, et al. A 48 week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virologic suppression of HAART. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22–25, 2005.
26
Miller MD, Margot NA, McColl DJ, Tran S, Coakley DF, Cheng AK. Genotypic and phenotypic characterization of virologic failure through 48 weeks among patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz. Presented at the 6th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, November 17–21, 2002.
27
Hirsch MS ,Brun-Vezinet F ,Clotet B , et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128
CrossRef | Web of Science | Medline
- Citing Articles (262)
Citing Articles
1
Innocent Omeje, Charles I Okwundu, Innocent Omeje. 2012. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. .
CrossRef2
Francesco Scaglione, Liberato Berrino. (2012) Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities. International Journal of Antimicrobial Agents
CrossRef3
Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg, Bruce R. Schackman. (2012) Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clinical Trials 13:1, 1-10
CrossRef4
Benjamin H. Chi, Albert Mwango, Mark J. Giganti, Izukanji Sikazwe, Crispin Moyo, Linnaea Schuttner, Lloyd B. Mulenga, Carolyn Bolton-Moore, Namwinga T. Chintu, Robert Sheneberger, Elizabeth M. Stringer, Jeffrey S. A. Stringer. (2011) Comparative Outcomes of Tenofovir-Based and Zidovudine-Based Antiretroviral Therapy Regimens in Lusaka, Zambia. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:5, 475-481
CrossRef5
V. von Wyl, S. Yerly, J. Boni, C. Shah, C. Cellerai, T. Klimkait, M. Battegay, E. Bernasconi, M. Cavassini, H. Furrer, B. Hirschel, P. L. Vernazza, B. Ledergerber, H. F. Gunthard, . (2011) Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases
CrossRef6
Christopher A. Kenedi, Harold W. Goforth. (2011) A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 15:8, 1803-1818
CrossRef7
Andrew Scourfield, Laura Waters, Mark Nelson. (2011) Drug combinations for HIV: what’s new?. Expert Review of Anti-infective Therapy 9:11, 1001-1011
CrossRef8
Jonathan Z. Li, Roger Paredes, Heather Ribaudo, Evguenia S. Svarovskaia, Michael J. Kozal, Katherine Huppler Hullsiek, Michael D. Miller, David Bangsberg, and Daniel R. Kuritzkes. (2011) Relationship between Minority NNRTI resistance mutations, adherence, and the risk of virologic failure. AIDS1
CrossRef9
Daniel R Kuritzkes. (2011) Drug resistance in HIV-1. Current Opinion in Virology
CrossRef10
Adrian Curran, Esteban Martinez, Maria Saumoy, Luis del Rio, Manuel Crespo, Maria Larrousse, Daniel Podzamczer, Joaquin Burgos, Montse Lonca, Pere Domingo, Jose Maria Gatell, Esteban Ribera. (2011) Body Composition Changes after Switching from Protease Inhibitors to Raltegravir. AIDS1
CrossRef11
M. W. Hull, J. S. G. Montaner. (2011) Optimizing Initial Therapy for HIV Infection. Journal of Infectious Diseases 204:8, 1154-1156
CrossRef12
P. E. Sax, C. Tierney, A. C. Collier, E. S. Daar, K. Mollan, C. Budhathoki, C. Godfrey, N. C. Jahed, L. Myers, D. Katzenstein, A. Farajallah, J. F. Rooney, B. Ha, W. C. Woodward, J. Feinberg, K. Tashima, R. L. Murphy, M. A. Fischl, . (2011) Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. Journal of Infectious Diseases 204:8, 1191-1201
CrossRef13
C.E. Sloan, K. Champenois, P. Choisy, E. Losina, R.P. Walensky, B.R. Schackman, F. Ajana, H. Melliez, A.D. Paltiel, K.A. Freedberg, Y. Yazdanpanah. (2011) Newer drugs and earlier treatment. AIDS1
CrossRef14
Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, Pere Domingo, Juan González-García, Juan Carlos López-Bernaldo, Josep M. Llibre, Fernando Lozano, Daniel Podzamczer, Juan Miguel Santamaría, Montserrat Tuset, Laura Zamora, Pablo Lázaro, Josep M. Gatell. (2011) Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial. Enfermedades Infecciosas y Microbiología Clínica
CrossRef15
Laura Albini, Bruno Mario Cesana, Davide Motta, Emanuele Focà, Daria Gotti, Alessandra Calabresi, Ilaria Izzo, Rita Bellagamba, Rita Fezza, Pasquale Narciso, Laura Sighinolfi, Paolo Maggi, Eugenia Quiros-Roldan, Luigi Manili, Giovanni Guaraldi, Giuseppe Lapadula, Carlo Torti. (2011) A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. JAIDS Journal of Acquired Immune Deficiency Syndromes1
CrossRef16
Erik De Clercq. 2011. HIV Life Cycle: Targets for Anti-HIV Agents. , 1-14.
CrossRef17
Josep M. Llibre, José R. Arribas, Pere Domingo, Josep M. Gatell, Fernando Lozano, José R. Santos, Antonio Rivero, Santiago Moreno, Bonaventura Clotet. (2011) Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 25:14, 1683-1690
CrossRef18
Erik De Clercq. 2011. Discovery and Development of Tenofovir Disoproxil Fumarate. , 85-101.
CrossRef19
G. A. McComsey, D. Kitch, P. E. Sax, P. Tebas, C. Tierney, N. C. Jahed, L. Myers, K. Melbourne, B. Ha, E. S. Daar. (2011) Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s. Clinical Infectious Diseases 53:2, 185-196
CrossRef20
Anita J. Brogan, Sandra E. Talbird, Calvin Cohen. (2011) Cost-Effectiveness of Nucleoside Reverse Transcriptase Inhibitor Pairs in Efavirenz-Based Regimens for Treatment-Naïve Adults with HIV Infection in the United States. Value in Health 14:5, 657-664
CrossRef21
S. P. Pushpakom, N. J. Liptrott, S. Rodriguez-Novoa, P. Labarga, V. Soriano, M. Albalater, E. Hopper-Borge, S. Bonora, G. Di Perri, D. J. Back, S. Khoo, M. Pirmohamed, A. Owen. (2011) Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. Journal of Infectious Diseases 204:1, 145-153
CrossRef22
Jean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel, Katia Boven. (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. The Lancet 378:9787, 238-246
CrossRef23
Calvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, Jan Fourie, Margaret A Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel, Katia Boven. (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. The Lancet 378:9787, 229-237
CrossRef24
Aoife G. Cotter, William G. Powderly. (2011) Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity. Best Practice & Research Clinical Endocrinology & Metabolism 25:3, 501-515
CrossRef25
Michael D. April, John J. Chiosi, A. David Paltiel, Paul E. Sax, Rochelle P. Walensky. (2011) Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal of General Internal Medicine 26:6, 661-667
CrossRef26
Allison C Ross, Andres Camacho-Gonzalez, Ann Chahroudi, Rana Chakraborty. (2011) Secondary complications and co-infections in the HIV-infected adolescent in the antiretroviral era. Current Opinion in Infectious Diseases 24:3, 212-218
CrossRef27
Esteban Martínez. (2011) Disorders of fat partitioning in treated HIV–infection. Best Practice & Research Clinical Endocrinology & Metabolism 25:3, 415-427
CrossRef28
Richard L. Mackman, Tomas Cihlar. 2011. Acyclic and Cyclic Nucleoside Phosphonates. , 91-128.
CrossRef29
Adrian Curran, Esteban Ribera. (2011) From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opinion on Drug Safety 10:3, 389-406
CrossRef30
Andrew M. Hall, Bruce M. Hendry, Dorothea Nitsch, John O. Connolly. (2011) Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence. American Journal of Kidney Diseases 57:5, 773-780
CrossRef31
P Menezes, JJ Eron, PA Leone, AA Adimora, DA Wohl, WC Miller. (2011) Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race. HIV Medicine 12:3, 183-191
CrossRef32
Shiro Ibe, Wataru Sugiura. (2011) Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiology 6:3, 295-315
CrossRef33
Fenglei Huang, Paul Scholl, David B. Huang, Thomas R. MacGregor, Mitchell E. Taub, Richard Vinisko, Mark A. Castles, Patrick Robinson. (2011) Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study. Basic & Clinical Pharmacology & Toxicology 108:3, 163-170
CrossRef34
Helen Bygrave, Nathan Ford, Gilles van Cutsem, Katherine Hilderbrand, Guillaume Jouquet, Eric Goemaere, Nathalie Vlahakis, Laura Triviño, Lipontso Makakole, Katharina Kranzer. (2011) Implementing a Tenofovir-Based First-Line Regimen in Rural Lesotho: Clinical Outcomes and Toxicities After Two Years. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:3, e75-e78
CrossRef35
HE Hsu, CE Rydzak, KL Cotich, B Wang, PE Sax, E Losina, KA Freedberg, SJ Goldie, Z Lu, RP Walensky, . (2011) Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Medicine 12:2, 97-108
CrossRef36
Gavin M. Myers, Kenneth H. Mayer. (2011) Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. AIDS Patient Care and STDs 25:2, 63-71
CrossRef37
Lisa B. Hightow-Weidman, Christopher B. Hurt, Gregory Phillips, Karen Jones, Manya Magnus, Thomas P. Giordano, Angulique Outlaw, Daniel Ramos, Elizabeth Enriquez-Bruce, Will Cobbs, Amy Wohl, Melinda Tinsle. (2011) Transmitted HIV-1 Drug Resistance Among Young Men of Color Who Have Sex With Men: A Multicenter Cohort Analysis. Journal of Adolescent Health 48:1, 94-99
CrossRef38
Mark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, Dénes Banhegyi, Brian Gazzard, Andrew Hill, Yvon van Delft, Johan Vingerhoets, Thomas Stark, Stephan Marks. (2011) A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 25:3, 335-340
CrossRef39
Derrick D Goodman, Yun Zhou, Nicolas A Margot, Damian J McColl, Lijie Zhong, Katyna Borroto-Esoda, Michael D Miller, Evguenia S Svarovskaia. (2011) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25:3, 325-333
CrossRef40
Laura Enomoto, Peter L. Anderson, Shaobing Li, Charles L. Edelstein, Adriana Weinberg. (2011) Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. AIDS Research and Human Retroviruses 27:1, 47-55
CrossRef41
Heidi M Crane, Carl Grunfeld, James H Willig, Michael J Mugavero, Stephen Van Rompaey, Richard Moore, Benigno Rodriguez, Betsy J Feldman, Michael M Lederman, Michael S Saag, Mari M Kitahata. (2011) Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 25:2, 185-195
CrossRef42
S. Gallien, V. Journot, W. Rozenbaum, P. Yeni, P. Morlat, I. Poizot-Martin, J. Reynes, V. Reliquet, P. Leclercq, F. Simon, G. Chene, J.-M. Molina, , J.- M. Molina, G. Chene, C. Rancinan, F. Collin, V. Journot, F. Ferchal, L. Morand-Joubert, P. Palmer, A. Charrois, J.- M. Molina, G. Chene, V. Journot, C. Rancinan, I. Madelaine, P. Morlat, W. Rozenbaum, D. Sereni, J. L. Vilde, F. Ferchal, L. Morand-Joubert, I. Poizot-Martin, E. Rosenthal, F. Raffi, J. Reynes. (2011) Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). Journal of Antimicrobial Chemotherapy 66:1, 184-191
CrossRef43
Kevin Peterson, Sabelle Jallow, Sarah L. Rowland-Jones, Thushan I. de Silva. (2011) Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Research and Treatment 2011, 1-11
CrossRef44
Eran Bendavid, Philip Grant, Annie Talbot, Douglas K Owens, Andrew Zolopa. (2011) Cost-effectiveness of antiretroviral regimens in the World Health Organizationʼs treatment guidelines: a South African analysis. AIDS 25:2, 211-220
CrossRef45
S Esser, A Haberl, F Mulcahy, J Gölz, A Lazzarin, E Teofilo, J Vera, A Körber, S Staszewski. (2011) Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study. European Journal of Medical Research 16:10, 427
CrossRef46
Emma D. Deeks, Caroline M. Perry. (2010) Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®). Drugs 70:17, 2315-2338
CrossRef47
Mark A. Boyd, Andrew M. Hill. (2010) Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. PharmacoEconomics 28, 17-34
CrossRef48
D. Soonawala, R. A. Middelburg, M. Egger, J. P. Vandenbroucke, O. M. Dekkers. (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology 39:6, 1567-1581
CrossRef49
Adriana Cadilla, Nadia Qureshi, Daniel C Johnson. (2010) Pediatric antiretroviral therapy. Expert Review of Anti-infective Therapy 8:12, 1381-1402
CrossRef50
Julio S G Montaner, Evan Wood, Thomas Kerr, Viviane Lima, Rolando Barrios, Kate Shannon, Richard Harrigan, Robert Hogg. (2010) Expanded Highly Active Antiretroviral Therapy Coverage Among HIV-Positive Drug Users to Improve Individual and Public Health Outcomes. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S5-S9
CrossRef51
Teresa L. Kauf, Raymond A. Farkouh, Stephanie R. Earnshaw, Maria E. Watson, Penny Maroudas, Mike G. Chambers. (2010) Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV. PharmacoEconomics 28:11, 1025-1039
CrossRef52
Alicen Spaulding, George W Rutherford, Nandi Siegfried, Alicen Spaulding. 2010. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. .
CrossRef53
Angela Ma, David M. Chen, Fern M. Chau, Parya Saberi. (2010) Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 22:10, 1189-1194
CrossRef54
Eugenia Quiros-Roldan, Silvia Amadasi, Giuseppe Paraninfo, Ilaria Izzo, Roberto Allegri, Davide Motta, Francesca Gatti, Graziella Cristini, Giampiero Carosi, Monia Mendeni, Carlo Torti. (2010) The Impact of Gender and Anchor Drugs on TDF Renal Toxicity. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, e11-e12
CrossRef55
Frank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, Pere Domingo, Daniel Podzamczer, Martin Fisher, Anthony G Norden, Matthias Cavassini, Armin Rieger, Marie-Aude Khuong-Josses, Teresa Branco, Helen C Pearce, Naomi Givens, Cindy Vavro, Michael L Lim. (2010) Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:1, 49-57
CrossRef56
D. F. Carr, C. J. L. la Porte, M. Pirmohamed, A. Owen, C. P. Cortes. (2010) Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. Journal of Antimicrobial Chemotherapy 65:9, 1889-1893
CrossRef57
Karen Wever, Michiel A van Agtmael, Andrew Carr. (2010) Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:1, 78-81
CrossRef58
Alicen Spaulding, George W Rutherford, Nandi Siegfried, Alicen Spaulding. 2010. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. .
CrossRef59
Jennifer Cohn, Brook Baker. (2010) Obstacles and Opportunities to Improve Antiretroviral Regimen Access in Low-Income Countries. Current HIV/AIDS Reports 7:3, 161-167
CrossRef60
Amanda Mocroft, Ole Kirk, Peter Reiss, Stephane De Wit, Dalibor Sedlacek, Marek Beniowski, Jose Gatell, Andrew N Phillips, Bruno Ledergerber, Jens D Lundgren. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24:11, 1667-1678
CrossRef61
M. Chowers, B.-S. Gottesman, L. Leibovici, J. M. Schapiro, M. Paul. (2010) Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 29:7, 779-786
CrossRef62
Daniel Drogan, Pia Rauch, Daniel Hoffmann, Hauke Walter, Karin J. Metzner. (2010) The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro. Antiviral Research 86:3, 312-315
CrossRef63
Panel de expertos de Gesida, Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, 362.e1-362.e91
CrossRef64
Mohammed I Danjuma, Atif Mohiuddin, Munir Pirmohamed, Saye Khoo. (2010) Tenofovir disoproxil fumarate and the kidney in HIV-infected patients: the evidence thus far. HIV Therapy 4:3, 345-359
CrossRef65
Vanessa Cooper, Rob Horne, Grace Gellaitry, Bernard Vrijens, Anne-Catherine Lange, Martin Fisher, David White. (2010) The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, 369-377
CrossRef66
Pablo Labarga, Jose Medrano, Eduardo Seclen, Eva Poveda, Sonia Rodriguez-Novoa, Judit Morello, Carmen de Mendoza, Eugenia Vispo, Vincent Soriano. (2010) Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS 24:5, 777-779
CrossRef67
Pere Domingo, Hernando Knobel, Félix Gutiérrez, Guillermina Barril, Xavier Fulladosa. (2010) Evaluación y tratamiento de la nefropatía en el paciente con infección por VIH-1. Una revisión práctica. Enfermedades Infecciosas y Microbiología Clínica 28:3, 185-198
CrossRef68
Miguel Goicoechea, Sonia Jain, Lucun Bi, Carol Kemper, Eric S Daar, Catherine Diamond, Belinda Ha, John Flaherty, Shelly Sun, Douglas Richman, Stan Louie, Richard Haubrich. (2010) Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 24:5, 707-716
CrossRef69
James A. McKinnell, James H. Willig, Andrew O. Westfall, Christa Nevin, Jeroan J. Allison, James L. Raper, Michael J. Mugavero, Michael S. Saag. (2010) Antiretroviral Prescribing Patterns in Treatment-Naïve Patients in the United States. AIDS Patient Care and STDs 24:2, 79-85
CrossRef70
Sally L. Hodder, Karam Mounzer, Edwin DeJesus, Ramin Ebrahimi, Kristy Grimm, Stephen Esker, Janet Ecker, Awny Farajallah, John F. Flaherty. (2010) Patient-Reported Outcomes in Virologically Suppressed, HIV-1–Infected Subjects After Switching to a Simplified, Single-Tablet Regimen of Efavirenz, Emtricitabine, and Tenofovir DF. AIDS Patient Care and STDs 24:2, 87-96
CrossRef71
Esteban Martinez, Fehmida Visnegarwala, Birgit Grund, Avis Thomas, Cynthia Gibert, Judith Shlay, Fraser Drummond, Daniel Pearce, Simon Edwards, Peter Reiss, Wafaa El-Sadr, Andrew Carr. (2010) The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 24:3, 353-563
CrossRef72
Tomas Cihlar, Adrian S. Ray. (2010) Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Research 85:1, 39-58
CrossRef73
Trevor Hawkins. (2010) Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Research 85:1, 201-209
CrossRef74
Jose R Arribas, Andrzej Horban, Jan Gerstoft, Gerdt Fätkenheuer, Mark Nelson, Nathan Clumeck, Federico Pulido, Andrew Hill, Yvon van Delft, Thomas Stark, Christiane Moecklinghoff. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24:2, 223-230
CrossRef75
José A. Esté, Tomas Cihlar. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Research 85:1, 25-33
CrossRef76
Joan F. Hilton. (2010) Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicinen/a-n/a
CrossRef77
Michael Horberg, Beth Tang, William Towner, Michael Silverberg, Susan Bersoff-Matcha, Leo Hurley, Joseph Chang, Jackie Blank, Charles Quesenberry, Daniel Klein. (2010) Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:1, 62-69
CrossRef78
Sax, Paul E., Tierney, Camlin, Collier, Ann C., Fischl, Margaret A., Mollan, Katie, Peeples, Lynne, Godfrey, Catherine, Jahed, Nasreen C., Myers, Laurie, Katzenstein, David, Farajallah, Awny, Rooney, James F., Ha, Belinda, Woodward, William C., Koletar, Susan L., Johnson, Victoria A., Geiseler, P. Jan, Daar, Eric S., . (2009) Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. New England Journal of Medicine 361:23, 2230-2240
Full Text79
Isaac Bogoch, Sharon Walmsley. (2009) First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach. Current Opinion in HIV and AIDS 4:6, 493-498
CrossRef80
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, 910-928
CrossRef81
Claudia Hawkins, Robert L Murphy. (2009) Management of antiretroviral failure and resistance in developing countries. Current Opinion in HIV and AIDS 4:6, 538-544
CrossRef82
James A McKinnell, Michael S Saag. (2009) Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C–C motif) receptor 5 antagonists]. Current Opinion in HIV and AIDS 4:6, 513-517
CrossRef83
Landovitz, Raphael J., Currier, Judith S., . (2009) Postexposure Prophylaxis for HIV Infection. New England Journal of Medicine 361:18, 1768-1775
Full Text84
Hassane Izzedine, Marianne Harris, Mark A. Perazella. (2009) The nephrotoxic effects of HAART. Nature Reviews Nephrology 5:10, 563-573
CrossRef85
Claudia A Hawkins, Beth Chaplin, John Idoko, Ernest Ekong, Isaac Adewole, Wadzani Gashau, Robert L Murphy, Phyllis Kanki. (2009) Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:2, 228-234
CrossRef86
Alice M Jenh, Chloe L Thio, Paul A Pham. (2009) Tenofovir for the Treatment of Hepatitis B Virus. Pharmacotherapy 29:10, 1212-1227
CrossRef87
Nicolas A Margot, Jeff Enejosa, Andrew K Cheng, Michael D Miller, Damian J McColl. (2009) Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:2, 209-221
CrossRef88
Joel E Gallant, Richard D Moore. (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23:15, 1971-1975
CrossRef89
Dan Turner, Eduardo Shahar, Eugene Katchman, Eynat Kedem, Natasha Matus, Michal Katzir, Gamal Hassoun, Shimon Pollack, Rivka Kessner, Mark A. Wainberg, Boaz Avidor. (2009) Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. Journal of Medical Virology 81:9, 1509-1512
CrossRef90
Leonardo Calza, Roberto Manfredi, Vincenzo Colangeli, Daria Pocaterra, Nirmala Rosseti, Michele Pavoni, Francesco Chiodo. (2009) Efficacy and Safety of Atazanavir-Ritonavir Plus Abacavir-Lamivudine or Tenofovir-Emtricitabine in Patients with Hyperlipidaemia Switched from a Stable Protease Inhibitor-Based Regimen Including One Thymidine Analogue. AIDS Patient Care and STDs 23:9, 691-697
CrossRef91
Ploenchan Chetchotisakd. (2009) The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Expert Review of Anti-infective Therapy 7:7, 801-805
CrossRef92
Brian P Kearney, Anita Mathias. (2009) Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives. Pharmacotherapy 29:8, 924-929
CrossRef93
Jean B. Nachega, Maria Paola Trotta, Mark Nelson, Adriana Ammassari. (2009) Impact of metabolic complications on antiretroviral treatment adherence: Clinical and public health implications. Current HIV/AIDS Reports 6:3, 121-129
CrossRef94
Benjamin Young, Kate Buchacz, Anne Moorman, Kathy C. Wood, John T. Brooks. (2009) Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study. AIDS Patient Care and STDs 23:8, 589-592
CrossRef95
Martin Fisher, Graeme J Moyle, Mohsen Shahmanesh, Chloe Orkin, Margaret Kingston, Edmund Wilkins, Jacqueline Ewan, Hui Liu, Ramin Ebrahimi, Geraldine Reilly. (2009) A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:5, 562-568
CrossRef96
M. Y. Chowers, B. S. Gottesman, L. Leibovici, U. Pielmeier, S. Andreassen, M. Paul. (2009) Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. Journal of Antimicrobial Chemotherapy 64:2, 239-250
CrossRef97
Silvia Baroncelli, Enrica Tamburrini, Marina Ravizza, Serena Dalzero, Cecilia Tibaldi, Enrico Ferrazzi, Gianfranco Anzidei, Marta Fiscon, Salvatore Alberico, Pasquale Martinelli, Giuseppina Placido, Giovanni Guaraldi, Carmela Pinnetti, Marco Floridia. (2009) Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. AIDS Patient Care and STDs 23:7, 513-520
CrossRef98
Dolly Sharma, Rana Chakraborty. (2009) Managing HIV infection in infants, children and adolescents with HAART. HIV Therapy 3:4, 391-404
CrossRef99
Dirk Lebrecht, Ana C Venhoff, Janbernd Kirschner, Thorsten Wiech, Nils Venhoff, Ulrich A Walker. (2009) Mitochondrial Tubulopathy in Tenofovir Disoproxil Fumarate-Treated Rats. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:3, 258-263
CrossRef100
Esteban Martínez, José A Arranz, Daniel Podzamczer, Montserrat Loncá, José Sanz, Patricia Barragán, Esteban Ribera, Hernando Knobel, Victor Roca, Félix Gutiérrez, José L Blanco, Josep Mallolas, Josep M Llibre, Bonaventura Clotet, David Dalmau, Ferran Segura, José R Arribas, Jaime Cosín, Pilar Barrufet, Esperanza Casas, Elena Ferrer, Adrià Curran, Alicia González, Judit Pich, Ana Cruceta, Joan A Arnaiz, José M Miró, José M Gatell. (2009) A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:3, 290-297
CrossRef101
Tom Delahunty, Lane Bushman, Brian Robbins, Courtney V. Fletcher. (2009) The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. Journal of Chromatography B 877:20-21, 1907-1914
CrossRef102
Mina C Hosseinipour, Joep JG van Oosterhout, Ralf Weigel, Sam Phiri, Debbie Kamwendo, Neil Parkin, Susan A Fiscus, Julie AE Nelson, Joseph J Eron, Johnstone Kumwenda. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23:9, 1127-1134
CrossRef103
Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez, Louis Sloan, Douglas J Ward, John F Flaherty, Ramin Ebrahimi, Jen-Fue Maa, Karen Reilly, Janet Ecker, Damian McColl, Daniel Seekins, Awny Farajallah. (2009) Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, 163-174
CrossRef104
Thor A Wagner, Nicole H Tobin, Jennifer L McKernan, Min Xu, Ann J Melvin, Kathleen M Mohan, Gerald H Learn, James I Mullins, Lisa M Frenkel. (2009) Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses. AIDS 23:8, 923-928
CrossRef105
Caroline A Sabin. (2009) Early antiretroviral therapy: the role of cohorts. Current Opinion in HIV and AIDS 4:3, 200-205
CrossRef106
Robert J. Fontana. (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S5, S185-S195
CrossRef107
Charlotte V Hobbs, Shaffiq M Essajee. (2009) Early treatment of HIV: implications for resource-limited settings. Current Opinion in HIV and AIDS1
CrossRef108
Mark A Boyd. (2009) Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS 4:3, 194-199
CrossRef109
Philip Grant, Andrew Zolopa. (2009) Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose. Current HIV/AIDS Reports 6:2, 63-67
CrossRef110
Makiko Kondo, Koji Sudo, Rie Tanaka, Takako Sano, Hiroko Sagara, Shinya Iwamuro, Yutaka Takebe, Mitsunobu Imai, Shingo Kato. (2009) Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR. Journal of Virological Methods 157:2, 141-146
CrossRef111
Drago Turčinov, Christine Stanley, George W. Rutherford, Thomas E. Novotny, Josip Begovac. (2009) Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy. European Journal of Epidemiology 24:5, 267-274
CrossRef112
Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Vishwottam Kandikere, Koteshwara Mudigonda, Prashanth Komarneni, Raghupathi Aleti, K. Mukkanti. (2009) Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. Biomedical Chromatography 23:4, 371-381
CrossRef113
Ei Kinai, Hideji Hanabusa. (2009) Progressive Renal Tubular Dysfunction Associated with Long-Term Use of Tenofovir DF. AIDS Research and Human Retroviruses 25:4, 387-394
CrossRef114
Awewura Kwara, Margaret Lartey, Kwamena W. Sagoe, Naser L. Rzek, Michael H. Court. (2009) CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British Journal of Clinical Pharmacology 67:4, 427-436
CrossRef115
Caroline A Sabin, Andrew N Phillips. (2009) Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients?. Current Opinion in Infectious Diseases 22:2, 191-197
CrossRef116
Bailing Xu, Yan Sun, Ying Guo, Yingli Cao, Tao Yu. (2009) Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry 17:7, 2767-2774
CrossRef117
John A Bartlett, Venance P Maro. (2009) Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution. HIV Therapy 3:2, 109-111
CrossRef118
Viviane Lima, Kimberly Fernandes, Beth Rachlis, Eric Druyts, Julio Montaner, Robert Hogg. (2009) Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Social Science & Medicine 68:6, 1044-1049
CrossRef119
Bret J. Rudy, Debra A. Murphy, D. Robert Harris, Larry Muenz, Jonathan Ellen. (2009) Patient-Related Risks for Nonadherence to Antiretroviral Therapy among HIV-Infected Youth in the United States: A Study of Prevalence and Interactions. AIDS Patient Care and STDs 23:3, 185-194
CrossRef120
Jean‐Jacques Parienti, David R. Bangsberg, Renaud Verdon, Edward M. Gardner. (2009) Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis. Clinical Infectious Diseases 48:4, 484-488
CrossRef121
Amina A. Chaudhry, Allen L. Gifford, Joseph Cofrancesco Jr., James Sosman, Gail Berkenblit, Lynn E. Sullivan. (2009) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 24:2, 276-282
CrossRef122
Mary C. Long, Jennifer R. King, Edward P. Acosta. (2009) Pharmacologic aspects of new antiretroviral drugs. Current HIV/AIDS Reports 6:1, 43-50
CrossRef123
Eoin J. Cotter, Patrick W. Mallon, Peter P. Doran. (2009) Is PPARγ a Prospective Player in HIV-1-Associated Bone Disease?. PPAR Research 2009, 1-9
CrossRef124
Anton Pozniak, Ravindra K. Gupta, Deenan Pillay, Jose Arribas, Andrew Hill. (2009) Causes and Consequences of Incomplete HIV RNA Suppression in Clinical Trials. HIV Clinical Trials 10:5, 289-298
CrossRef125
Anthony Amoroso, Bruce L. Gilliam, Rohit Talwani, Colleen Boyce, Robert R. Redfield, Charles E. Davis. (2009) Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine. HIV Clinical Trials 10:5, 320-323
CrossRef126
Wouter FW Bierman, Michiel A van Agtmael, Monique Nijhuis, Sven A Danner, Charles AB Boucher. (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23:3, 279-291
CrossRef127
Mohamed G. Atta, Gilbert Deray, Gregory M. Lucas. (2008) Antiretroviral Nephrotoxicities. Seminars in Nephrology 28:6, 563-575
CrossRef128
Mary C. Long, Jennifer R. King, Edward P. Acosta. (2008) Pharmacologic aspects of new antiretroviral drugs. Current Infectious Disease Reports 10:6, 522-529
CrossRef129
Kimberly A Struble, Kirk M Chan-Tack, Guoxing (Greg) Soon. (2008) Regulatory issues in developing new HIV protease inhibitors: risks and benefits. Current Opinion in HIV and AIDS 3:6, 676-680
CrossRef130
Erik De Clercq. (2008) The discovery of antiviral agents: Ten different compounds, ten different stories. Medicinal Research Reviews 28:6, 929-953
CrossRef131
M. Crespo, E. Ribera, I. Suarez-Lozano, P. Domingo, E. Pedrol, J. Lopez-Aldeguer, A. Munoz, C. Vilades, T. Sanchez, P. Viciana, R. Teira, M. L. Garcia-Alcalde, A. Vergara, F. Lozano, M. J. Galindo, J. Cosin, B. Roca, A. Terron, P. Geijo, F. Vidal, M. Garrido, . (2008) Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. Journal of Antimicrobial Chemotherapy 63:1, 189-196
CrossRef132
David A. Wohl, David Waters, Ross J. Simpson, Susan Richard, Amanda Schnell, Sonia Napravnik, Jessica Keys, J. Joseph Eron, Priscilla Hsue. (2008) Ezetimibe Alone Reduces Low‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy. Clinical Infectious Diseases 47:8, 1105-1108
CrossRef133
Juan Berenguer, Juan González, Esteban Ribera, Pere Domingo, Jesús Santos, Pilar Miralles, Mª Angels Ribas, Víctor Asensi, Juan Luis Gimeno, José Antonio Pérez‐Molina, José Alberto Terrón, Juan Miguel Santamaría, Enric Pedrol, . (2008) Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903. Clinical Infectious Diseases 47:8, 1083-1092
CrossRef134
R. E. Barth, J. T. M. Meer, A. I. M. Hoepelman, P. A. Schrooders, D. A. Vijver, S. P. M. Geelen, H. A. Tempelman. (2008) Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. European Journal of Clinical Microbiology & Infectious Diseases 27:10, 977-984
CrossRef135
Julian H Elliott, Lut Lynen, Alexandra Calmy, Andrea De Luca, Robert W Shafer, Maria Zolfo, Bonaventura Clotet, Sarah Huffam, Charles AB Boucher, David A Cooper, Jonathan M Schapiro. (2008) Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 22:16, 2053-2067
CrossRef136
Alexandre B Libório, Lúcia Andrade, Leonardo V B Pereira, Talita R C Sanches, Maria H Shimizu, Antonio C Seguro. (2008) Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney International 74:7, 910-918
CrossRef137
Bruce R Schackman, Callie A Scott, Rochelle P Walensky, Elena Losina, Kenneth A Freedberg, Paul E Sax. (2008) The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22:15, 2025-2033
CrossRef138
Manuel Leal, Ángela Camacho, Miguel Genebat, Antonio Rivero. (2008) ¿En qué momento y con qué combinaciones debería indicarse maraviroc en el nuevo escenario del tratamiento antirretroviral?. Enfermedades Infecciosas y Microbiología Clínica 26, 34-39
CrossRef139
Katherine R. Waite, Michael Paasche-Orlow, Lance S. Rintamaki, Terry C. Davis, Michael S. Wolf. (2008) Literacy, Social Stigma, and HIV Medication Adherence. Journal of General Internal Medicine 23:9, 1367-1372
CrossRef140
Ravindra Gupta, Andrew Hill, Anthony W. Sawyer, Deenan Pillay. (2008) Emergence of Drug Resistance in HIV Type 1–Infected Patients after Receipt of First‐Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials. Clinical Infectious Diseases 47:5, 712-722
CrossRef141
A. Pozniak. (2008) Tenofovir: what have over 1 million years of patient experience taught us?. International Journal of Clinical Practice 62:8, 1285-1293
CrossRef142
Cooper, David A., Steigbigel, Roy T., Gatell, Jose M., Rockstroh, Jurgen K., Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Kumar, Princy N., Eron, Joseph E., Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R., Lennox, Jeffrey L., Zhao, Jing, Chen, Joshua, Ryan, Desmond M., Rhodes, Rand R., Killar, John A., Gilde, Lucinda R., Strohmaier, Kim M., Meibohm, Anne R., Miller, Michael D., Hazuda, Daria J., Nessly, Michael L., DiNubile, Mark J., Isaacs, Robin D., Teppler, Hedy, Nguyen, Bach-Yen, . (2008) Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine 359:4, 355-365
Full Text143
M. Lafaurie, F. Collin, M. Bentata, M. Garre, C. Leport, Y. Levy, C. Goujard, G. Chene, J.-M. Molina, . (2008) Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. Journal of Antimicrobial Chemotherapy 62:5, 1122-1129
CrossRef144
Albert M. L. Anderson, Jeffrey L. Lennox. (2008) Antiretroviral therapy: When to start and which drugs to use. Current Infectious Disease Reports 10:4, 332-339
CrossRef145
(2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 372:9635, 293-299
CrossRef146
Kari Yacisin, Ivana Maida, María José Ríos, Vincent Soriano, Marina Núñez. (2008) Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy. AIDS Research and Human Retroviruses 24:7, 935-940
CrossRef147
Marianne Harris. (2008) Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Drug Safety 7:4, 389-400
CrossRef148
Elena Ferrer, Jose Maria Gatell, Pochita Sanchez, Pere Domingo, Teresa Puig, Jordi Niubo, Cristina Cortes, Sergio Veloso, Enric Pedrol, Agathe Leon, Mar Gutierrez, Daniel Podzamczer. (2008) Zidovudine/Lamivudine/Abacavir Plus Tenofovir in HIV-Infected Naive Patients: A 96-Week Prospective One-Arm Pilot Study. AIDS Research and Human Retroviruses 24:7, 931-934
CrossRef149
C. Duvivier, J. Ghosn, L. Assoumou, C. Soulie, G. Peytavin, V. Calvez, M. A. Genin, J.-M. Molina, O. Bouchaud, C. Katlama, D. Costagliola, . (2008) Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. Journal of Antimicrobial Chemotherapy 62:4, 797-808
CrossRef150
Federico Pulido, Silvana Fiorante. (2008) Datos clínicos II. Experiencia clínica de tenofovir en combinaciones con inhibidores de proteasa. Enfermedades Infecciosas y Microbiología Clínica 26, 13-18
CrossRef151
José Ignacio Bernardino de la Serna, Marta Mora Rillo, José Ramón Arribas López. (2008) Datos clínicos I. Experiencia clínica de tenofovir en combinaciones con inhibidores no análogos de la transcriptasa inversa. Enfermedades Infecciosas y Microbiología Clínica 26, 7-12
CrossRef152
Josep Mallolas. (2008) Conclusiones. Enfermedades Infecciosas y Microbiología Clínica 26, 62-64
CrossRef153
Celia Miralles Álvarez. (2008) ¿Son iguales todas las combinaciones de análogos?. Enfermedades Infecciosas y Microbiología Clínica 26, 38-44
CrossRef154
Joaquín Portilla. (2008) Tenofovir como estrategia para evitar o detener efectos adversos. Enfermedades Infecciosas y Microbiología Clínica 26, 19-24
CrossRef155
Esteban Ribera Pascuet, Adria Curran. (2008) Papel actual de tenofovir en la clínica. Enfermedades Infecciosas y Microbiología Clínica 26, 45-54
CrossRef156
Martin S. Hirsch. (2008) Initiating Therapy: When to Start, What to Use. The Journal of Infectious Diseases 197:s3, S252-S260
CrossRef157
Hirschel, Bernard, Calmy, Alexandra, . (2008) Initial Treatment for HIV Infection — An Embarrassment of Riches. New England Journal of Medicine 358:20, 2170-2172
Full Text158
Benjamin J Eckhardt, Marshall J Glesby. (2008) Antiretroviral therapy and cardiovascular risk: are some medications cardioprotective?. Current Opinion in HIV and AIDS 3:3, 226-233
CrossRef159
Andrew Hill, Caroline Sabin. (2008) Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 22:8, 913-921
CrossRef160
Christoph Stephan. (2008) Experience with tenofovir disoproxil fumarate for antiretroviral therapy. Expert Opinion on Pharmacotherapy 9:7, 1197-1209
CrossRef161
C. Delaugerre, P. Flandre, A.G. Marcelin, D. Descamps, C. Tamalet, J. Cottalorda, V. Schneider, S. Yerly, J. LeGoff, L. Morand-Joubert, M.L. Chaix, D. Costagliola, V. Calvez, . (2008) National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. Journal of Medical Virology 80:5, 762-765
CrossRef162
Marisa Tungsiripat, Grace McComsey. (2008) Pathogenesis and management of lipoatrophy. Current HIV/AIDS Reports 5:2, 55-63
CrossRef163
Florian van Bömmel, Thomas Berg. (2008) Role of tenofovir in the treatment of chronic HBV infection. Future Virology 3:3, 207-220
CrossRef164
Viktor von Wyl, Sabine Yerly, Jürg Böni, Philippe Bürgisser, Thomas Klimkait, Manuel Battegay, Enos Bernasconi, Matthias Cavassini, Hansjakob Furrer, Bernard Hirschel, Pietro L. Vernazza, Martin Rickenbach, Bruno Ledergerber, Huldrych F. Günthard, . (2008) Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. Clinical Infectious Diseases 46:8, 1299-1309
CrossRef165
Derek M. Fine, Mark A. Perazella, Gregory M. Lucas, Mohamed G. Atta. (2008) Kidney Biopsy in HIV: Beyond HIV-Associated Nephropathy. American Journal of Kidney Diseases 51:3, 504-514
CrossRef166
Constantine G. Boojamra, Richard L. Mackman, David Y. Markevitch, Vidya Prasad, Adrian S. Ray, Janet Douglas, Deborah Grant, Choung U. Kim, Tomas Cihlar. (2008) Synthesis and anti-HIV activity of GS-9148 (2′-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. Bioorganic & Medicinal Chemistry Letters 18:3, 1120-1123
CrossRef167
N Clumeck, A Pozniak, F Raffi, . (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Medicine 9:2, 65-71
CrossRef168
Rainel Sánchez-de la Rosa, Luis Herrera, Santiago Moreno. (2008) Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Clinical Therapeutics 30:2, 372-381
CrossRef169
JJ Kiser, ML Carten, CL Aquilante, PL Anderson, P Wolfe, TM King, T Delahunty, LR Bushman, CV Fletcher. (2008) The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients. Clinical Pharmacology & Therapeutics 83:2, 265-272
CrossRef170
Derek M Fine, Mark A Perazella, Gregory M Lucas, Mohamed G Atta. (2008) Renal Disease in Patients with HIV Infection. Drugs 68:7, 963-980
CrossRef171
Carlo Giaquinto, Erika Morelli, Federica Fregonese, Osvalda Rampon, Martina Penazzato, Anita de Rossi, Ruggero D’Elia. (2008) Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection. Clinical Drug Investigation 28:6, 375-397
CrossRef172
Jose R Arribas, Anton L Pozniak, Joel E Gallant, Edwin DeJesus, Brian Gazzard, Rafael E Campo, Shan-Shan Chen, Damian McColl, Charles B Holmes, Jeffrey Enejosa, John J Toole, Andrew K Cheng. (2008) Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, 74-78
CrossRef173
Christopher N Tymchuk, Judith S Currier. (2008) The safety of antiretroviral drugs. Expert Opinion on Drug Safety 7:1, 1-4
CrossRef174
Giordano Madeddu, Paolo Bonfanti, Giuseppe V. De Socio, Silvia Carradori, Carmela Grosso, Patrizia Marconi, Giovanni Penco, Elena Rosella, Sebastiano Miccolis, Sara Melzi, Maria Stella Mura, Simona Landonio, Elena Ricci, Tiziana Quirino, for the CISAI Group. (2008) Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project. Biomedicine & Pharmacotherapy 62:1, 6-11
CrossRef175
Wendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, Amanda Mocroft, Ole Kirk, Schlomo Staszewski, Clive Loveday, Anders Karlsson, Antonella dʼArminio Monforte, Bonaventura Clotet, Jens D Lundgren. (2008) Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 22:3, 367-376
CrossRef176
Jean-Michel Molina. (2008) Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection. Drugs 68:5, 567-578
CrossRef177
Erik De Clercq. (2007) The design of drugs for HIV and HCV. Nature Reviews Drug Discovery 6:12, 1001-1018
CrossRef178
Charles Flexner. (2007) HIV drug development: the next 25 years. Nature Reviews Drug Discovery 6:12, 959-966
CrossRef179
Olga Delgado Sánchez, Francesc Puigventós Latorre, Manel Pinteño Blanco, Pere Ventayol Bosch. (2007) Equivalencia terapéutica: concepto y niveles de evidencia. Medicina Clínica 129:19, 736-745
CrossRef180
Chandra Y. Osborn, Michael K. Paasche-Orlow, Terry C. Davis, Michael S. Wolf. (2007) Health Literacy. American Journal of Preventive Medicine 33:5, 374-378
CrossRef181
Derek M. Fine, Mohamed G. Atta. (2007) Review: Kidney Disease in the HIV-Infected Patient. AIDS Patient Care and STDs 21:11, 813-824
CrossRef182
C William Wester, Okechukwu A Okezie, Ann Muir Thomas, Hermann Bussmann, Sikhulile Moyo, Tanaka Muzenda, Joseph Makhema, Erik van Widenfelt, Rosemary Musonda, Vladimir Novitsky, Tendani Gaolathe, Ndwapi Ndwapi, Max Essex, Daniel R Kuritzkes, Victor deGruttola, Richard G Marlink. (2007) Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:3, 318-322
CrossRef183
Elena Ferrer, Jordi Niubo, Manel Crespo, Josep Maria Gatell, Jose Sanz, Sergio Veloso, Josep Maria Llibre, Pilar Barrufet, Pochita Sanchez, Daniel Podzamczer. (2007) Genotypic Resistance in HIV-Infected Naive Patients Receiving Abacavir Plus Lamivudine and Efavirenz. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:2, 253-255
CrossRef184
Gerrit Schreij, Robert Janknegt. (2007) InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor ‘backbones’. Expert Opinion on Pharmacotherapy 8:S1, S37-S47
CrossRef185
Anita A Mathias, John Hinkle, Mark Menning, James Hui, Sanjeev Kaul, Brian P Kearney. (2007) Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:2, 167-173
CrossRef186
Alessandro Soria, Adriano Lazzarin. (2007) Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:Suppl 1, S19-S30
CrossRef187
Christian Manzardo, Mauro Zaccarelli, Fernando Ag??ero, Andrea Antinori, Jos?? M Mir??. (2007) Optimal Timing and Best Antiretroviral Regimen in Treatment-naive HIV-Infected Individuals with Advanced Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:Suppl 1, S9-S18
CrossRef188
Mark A Wainberg, Jorge L Martinez-Cajas, Bluma G Brenner. (2007) Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance. Future HIV Therapy 1:3, 291-313
CrossRef189
J. H. Willig, A. O. Westfall, J. Allison, N. V. Wagoner, P.-W. Chang, J. Raper, M. S. Saag, M. J. Mugavero. (2007) Nucleoside Reverse-Transcriptase Inhibitor Dosing Errors in an Outpatient HIV Clinic in the Electronic Medical Record Era. Clinical Infectious Diseases 45:5, 658-661
CrossRef190
A S Levey, R Atkins, J Coresh, E P Cohen, A J Collins, K-U Eckardt, M E Nahas, B L Jaber, M Jadoul, A Levin, N R Powe, J Rossert, D C Wheeler, N Lameire, G Eknoyan. (2007) Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney International 72:3, 247-259
CrossRef191
María del Mar Gutierrez, Gracia Mateo, Pere Domingo. (2007) Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion on Pharmacotherapy 8:12, 1871-1884
CrossRef192
David Alain Wohl. (2007) Considering metabolic issues when initiating HIV therapy. Current HIV/AIDS Reports 4:3, 119-125
CrossRef193
Michael P Dub??, Lauren Komarow, Kathleen Mulligan, Steven K Grinspoon, Robert A Parker, Gregory K Robbins, Ronenn Roubenoff, Pablo Tebas. (2007) Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:5, 508-514
CrossRef194
2007. Human Immunodeficiency Virus (HIV). .
CrossRef195
Sander I van Leuven, Raaj R Sankatsing, Joost N Vermeulen, John JP Kastelein, Peter Reiss, Erik SG Stroes. (2007) Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Current Opinion in HIV and AIDS 2:4, 324-331
CrossRef196
David H Shepp, Sue Curtis, James F Rooney. (2007) Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. AIDS 21:11, 1479-1481
CrossRef197
Marta Boffito, Alan Winston, Akil Jackson, Carl Fletcher, Anton Pozniak, Mark Nelson, Graeme Moyle, Izabela Tolowinska, Richard Hoetelmans, Diego Miralles, Brian Gazzard. (2007) Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 21:11, 1449-1455
CrossRef198
Nicholas S Chew, Peter P Doran, William G Powderly. (2007) Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Current Opinion in HIV and AIDS 2:4, 318-323
CrossRef199
Mark R Nelson, Christine Katlama, Julio S Montaner, David A Cooper, Brian Gazzard, Bonaventura Clotet, Adriano Lazzarin, Knud Schewe, Joep Lange, Christina Wyatt, Sue Curtis, Shan-Shan Chen, Stephen Smith, Norbert Bischofberger, James F Rooney. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21:10, 1273-1281
CrossRef200
Sharon Walmsley. (2007) Protease Inhibitor-Based Regimens for HIV Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 1, S5-S13
CrossRef201
R. Jones, C. Scott, M. Nelson, J. Levy. (2007) Renal complications in HIV. International Journal of Clinical Practice 61:6, 991-998
CrossRef202
Brian Conway. (2007) The Role of Adherence to Antiretroviral Therapy in the Management of HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:Supplement 1, S14-S18
CrossRef203
Jennifer J. Kiser, Courtney V. Fletcher. 2007. The Clinical Pharmacology of Nucleoside Reverse Transcriptase Inhibitors. , 279-294.
CrossRef204
Franco Maggiolo. (2007) Efavirenz. Expert Opinion on Pharmacotherapy 8:8, 1137-1145
CrossRef205
L. Waters, M. Nelson. (2007) Why do patients fail HIV therapy?. International Journal of Clinical Practice 61:6, 983-990
CrossRef206
L. Waters, M. Nelson. (2007) Long-term complications of antiretroviral therapy: lipoatrophy. International Journal of Clinical Practice 61:6, 999-1014
CrossRef207
Kristel Van Laethem, Paul De Munter, Yoeri Schrooten, Rene Verbesselt, Marc Van Ranst, Eric Van Wijngaerden, Anne-Mieke Vandamme. (2007) No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs. Journal of Clinical Virology 39:1, 43-47
CrossRef208
Angela C Huttner, Gilbert R Kaufmann, Manuel Battegay, Rainer Weber, Milos Opravil. (2007) Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. AIDS 21:8, 939-946
CrossRef209
Joel E. Gallant. (2007) Should antiretroviral therapy be started earlier?. Current HIV/AIDS Reports 4:2, 53-59
CrossRef210
Ravindra Kumar Gupta, Deenan Pillay. (2007) HIV resistance and the developing world. International Journal of Antimicrobial Agents 29:5, 510-517
CrossRef211
Kathryn Anastos, Dalian Lu, Qiuhu Shi, Phyllis C Tien, Robert C Kaplan, Nancy A Hessol, Steven Cole, Cheryl Vigen, Mardge Cohen, Mary Young, Jessica Justman. (2007) Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:1, 34-42
CrossRef212
Marc Vekemans, Laurence John, Robert Colebunders. (2007) When to switch for antiretroviral treatment failure in resource-limited settings?. AIDS 21:9, 1205-1206
CrossRef213
Jintanat Ananworanich. (2007) Reaching undetectable viral loads after initial HIV treatment. Future HIV Therapy 1:1, 81-89
CrossRef214
(2007) Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 21:8, 947-955
CrossRef215
Raffaele Bruno, Paolo Sacchi, Gaetano Filice. (2007) Could Tenofovir Modify the Model End-Stage Liver Disease (MELD) Score in Patients With End-Stage Liver Disease Eligible for Liver Transplantation?. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:1, 123
CrossRef216
Fatu Forna, Cheryl A Liechty, Peter Solberg, Fred Asiimwe, Willy Were, Jonathan Mermin, Prosper Behumbiize, Tony Tong, John T Brooks, Paul J Weidle. (2007) Clinical Toxicity of Highly Active Antiretroviral Therapy in a Home-Based AIDS Care Program in Rural Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:4, 456-462
CrossRef217
Saskia ME Vrouenraets, Ferdinand WNM Wit, Jacqueline van Tongeren, Joep MA Lange. (2007) Efavirenz: a review. Expert Opinion on Pharmacotherapy 8:6, 851-871
CrossRef218
E Hart, H Curtis, E Wilkins, M Johnson. (2007) National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-na
ve patients. HIV Medicine 8:3, 186-191
CrossRef219
Srinivasan Ramanathan, Gong Shen, Andrew Cheng, Brian P Kearney. (2007) Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137. JAIDS Journal of Acquired Immune Deficiency Syndromes PAP,
CrossRef220
Roy M. Gulick. (2007) Antiretroviral Management of Treatment-Naive Patients. Infectious Disease Clinics of North America 21:1, 71-84
CrossRef221
Michael D Gitman, David Hirschwerk, Cindy H Baskin, Pravin C Singhal. (2007) Tenofovir-induced kidney injury. Expert Opinion on Drug Safety 6:2, 155-164
CrossRef222
Joel E. Gallant. (2007) Approach to the Treatment-Experienced Patient. Infectious Disease Clinics of North America 21:1, 85-102
CrossRef223
Miguel Goicoechea, Brookie Best. (2007) Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. Expert Opinion on Pharmacotherapy 8:3, 371-382
CrossRef224
Michael S. Wolf, Terry C. Davis, Chandra Y. Osborn, Silvia Skripkauskas, Charles L. Bennett, Gregory Makoul. (2007) Literacy, self-efficacy, and HIV medication adherence. Patient Education and Counseling 65:2, 253-260
CrossRef225
Gail Matthews. (2007) The management of HIV and hepatitis B coinfection. Current Opinion in Infectious Diseases 20:1, 16-21
CrossRef226
D.R. Snydman. (2007) Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. Yearbook of Medicine 2007, 58-59
CrossRef227
&NA;. (2007) A Once-Daily Combination Tablet (Atripla) for HIV. Obstetrics & Gynecology 109:1, 195-196
CrossRef228
David M. Brett-Major, Anuradha Ganesan. (2007) Dyslipidemia Management in Patients With Human Immunodeficiency Virus. Infectious Diseases in Clinical Practice 15:1, 7-16
CrossRef229
Peter Hynes, Antonio Urbina, Alexander McMeeking, Laura Barisoni, Rahmin Rabenou. (2007) Acute Renal Failure after Initiation of Tenofovir Disoproxil Fumarate. Renal Failure 29:8, 1063-1066
CrossRef230
Sreevani Vemuri, Jeffrey Bratberg, Karen Burke, Gail Skowron. (2007) Truvada intolerance. AIDS 21:3, 382-383
CrossRef231
L. Waters, L. John, M. Nelson. (2007) Non-nucleoside reverse transcriptase inhibitors: a review. International Journal of Clinical Practice 61:1, 105-118
CrossRef232
Laura Waters, Graeme Moyle. (2006) Abacavir/lamividune combination in the treatment of HIV-1 infection: a review. Expert Opinion on Pharmacotherapy 7:18, 2571-2580
CrossRef233
Kate Buchacz, Benjamin Young, Rose K Baker, Anne Moorman, Joan S Chmiel, Kathy C Wood, John T Brooks. (2006) Renal Function in Patients Receiving Tenofovir With Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:5, 626-628
CrossRef234
Anton Pozniak. (2006) Initiation of antiretroviral therapy. Current Opinion in Internal Medicine 5:6, 594-604
CrossRef235
Rosario Palacios, Isabel Aguilar, Ana Hidalgo, Jesús Santos. (2006) Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Expert Review of Anti-infective Therapy 4:6, 965-971
CrossRef236
Erik De Clercq. (2006) From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virology 1:6, 709-715
CrossRef237
B Gazzard, . (2006) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine 7:8, 487-503
CrossRef238
Abdel G Babiker, Diana M Gibb. (2006) Considerations in the design of randomized controlled trials evaluating the optimal time to initiate antiretroviral therapy in previously untreated HIV-1-infected patients. Current Opinion in HIV and AIDS 1:6, 488-494
CrossRef239
Anton L Pozniak, Joel E Gallant, Edwin DeJesus, Jose R Arribas, Brian Gazzard, Rafael E Campo, Shan-Shan Chen, Damian McColl, Jeffrey Enejosa, John J Toole, Andrew K Cheng. (2006) Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes PAP,
CrossRef240
Christine Katlama, Jade Ghosn. (2006) Clinical trials for heavily pretreated patients: update in 2006. Current Opinion in HIV and AIDS 1:6, 495-501
CrossRef241
Paul E Sax. (2006) Evaluation and management of early virological failure. Current Opinion in HIV and AIDS 1:5, 409-416
CrossRef242
Tomas Cihlar. (2006) Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Current Opinion in HIV and AIDS 1:5, 373-379
CrossRef243
Jeffrey Laurence. (2006) Treating HIV Infection with One Pill Per Day. AIDS Patient Care and STDs 20:9, 601-603
CrossRef244
Raymond F. Schinazi, Brenda I. Hernandez-Santiago, Selwyn J. Hurwitz. (2006) Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Research 71:2-3, 322-334
CrossRef245
Julio SG Montaner, Robert Hogg, Evan Wood, Thomas Kerr, Mark Tyndall, Adrian R Levy, P Richard Harrigan. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. The Lancet 368:9534, 531-536
CrossRef246
Joseph Eron, Patrick Yeni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Schlomo Staszewski, Philip Lackey, Christine Katlama, Benjamin Young, Linda Yau, Denise Sutherland-Phillips, Paul Wannamaker, Cindy Vavro, Lisa Patel, Jane Yeo, Mark Shaefer. (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. The Lancet 368:9534, 476-482
CrossRef247
Rosa María Muñoz de Benito, Jose Ramón Arribas López. (2006) Tenofovir disoproxil fumarate–emtricitabine coformulation for once-daily dual NRTI backbone. Expert Review of Anti-infective Therapy 4:4, 523-535
CrossRef248
J. Stebbing, M. Bower, S. Mandalia, M. Nelson, B. Gazzard. (2006) Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clinical and Experimental Immunology 145:2, 271-276
CrossRef249
Gregory J Dore, David A Cooper. (2006) HAART's first decade: success brings further challenges. The Lancet 368:9534, 427-428
CrossRef250
Matthias Götte, Mark A Wainberg. (2006) Significance of the L74V mutation in HIV-1 reverse transcriptase. Future Virology 1:4, 493-500
CrossRef251
Joel E. Gallant, Michael L. Lim, Mark S. Shaefer. (2006) Reply to Carr. The Journal of Infectious Diseases 193:12, 1742-1743
CrossRef252
(2006) Tenofovir DF and Emtricitabine vs. Zidovudine and Lamivudine. New England Journal of Medicine 354:23, 2506-2508
Full Text253
J. A. Winston, D. H. Shepp. (2006) The Role of Drug Interactions and Monitoring in the Prevention of Tenofovir-Associated Kidney Disease. Clinical Infectious Diseases 42:11, 1657-1658
CrossRef254
Rafik Samuel, Robert Bettiker, Byungse Suh. (2006) Antiretroviral therapy 2006: Pharmacology, applications, and special situations. Archives of Pharmacal Research 29:6, 431-458
CrossRef255
Cunlin Wang, Saba W. Masho, Daniel E. Nixon. (2006) When to start antiretroviral therapy. Current HIV/AIDS Reports 3:2, 66-73
CrossRef256
Karen T. Tashima, Jennifer Adelson Mitty. (2006) Once-daily therapies for the treatment of HIV infection. Current HIV/AIDS Reports 3:2, 86-92
CrossRef257
Emil Lesho. (2006) Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Review of Anti-infective Therapy 4:3, 469-478
CrossRef258
Paul A Pham, Joel E Gallant. (2006) Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opinion on Drug Metabolism & Toxicology 2:3, 459-469
CrossRef259
Bluma G Brenner, Maureen Oliveira, Florence Doualla-Bell, Daniela D Moisi, Michel Ntemgwa, Fernando Frankel, Max Essex, Mark A Wainberg. (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:9, F9-F13
CrossRef260
Christina M Wyatt, Paul E Klotman. (2006) Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opinion on Drug Safety 5:2, 275-287
CrossRef261
Brian P Kearney, Kitty Yale, Jaymin Shah, Lijie Zhong, John F Flaherty. (2006) Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment. Clinical Pharmacokinetics 45:11, 1115-1124
CrossRef262
James E Frampton, Katherine F Croom. (2006) Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate. Drugs 66:11, 1501-1512
CrossRef
- Letters
